First human trial of a new antibody drug begins
NCT ID NCT07713485
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests the safety and tolerability of a new drug called XmAb412, a monoclonal bispecific antibody, in healthy adults aged 18 to 55. Participants receive either the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. The goal is to gather early safety data before testing the drug in people with specific diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- XmAb412, a monoclonal bispecific antibody
- What this could lead to
- If safe and well-tolerated, this could pave the way for future studies of XmAb412 in specific diseases.
- What could go wrong
- This is an early, small Phase 1 trial focused on safety, not efficacy. The drug may not work or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOT APPLICABLE - HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Xencor Investigative Site
RECRUITINGJoondalup, Western Australia, 6027, Australia
-
Xencor Investigative Site
RECRUITINGNedlands, Western Australia, 6009, Australia